Metraipolis › archive › dc_d804067cc8ca

Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung… — Europe PMC PMID:42643500

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42643500
DOI
10.3389/fimmu.2026.1879524
License (as archived)
solo-consultazione
Archived
2026-10-16T21:43:06.747Z
SHA-256 of the archived text
cbc2f6f9a1367d2a33244bffe02bc4e69cbd9aee91c94f2bf47a966f37aa3ee2
Stable URL of this page
https://metraipolis.com/documento/dc_d804067cc8ca

How to cite

Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung… — Europe PMC PMID:42643500 — Europe PMC (en), https://europepmc.org/article/MED/42643500 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d804067cc8ca (Metraipolis archive dc_d804067cc8ca, sha256 cbc2f6f9a1367d2a33244bffe02bc4e69cbd9aee91c94f2bf47a966f37aa3ee2)
BibTeX
@misc{dcd804067cc8ca,
  title = {Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung… — Europe PMC PMID:42643500},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42643500},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d804067cc8ca; sha256 cbc2f6f9a1367d2a33244bffe02bc4e69cbd9aee91c94f2bf47a966f37aa3ee2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42643500. Agents can read the archived copy with the MCP tool read_document.